Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.36 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.36 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.34 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | SELE | P16581 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181345 | 0.85 | IDO1 (0.45) | ALDH1A1KMT2ANPSR1SLC2A1IDO1 | |
| SCHEMBL5388770 | 0.84 | PELI1 (0.44) | KCNA3 | |
| SCHEMBL5388767 | 0.84 | PELI1 (0.44) | KCNA3 | |
| SCHEMBL3172066 | 0.82 | ALDH1A1 (0.56) | ALDH1A1NPFFR2KMT2ANPSR1 | |
| SCHEMBL3161665 | 0.82 | PLA2G7 (0.49) | ALDH1A1KMT2AIDO1PLA2G7 | |
| SCHEMBL16649786 | 0.79 | KCNA3 (0.36) | KCNA3KMOKCNQ3KCNQ2KCNE1 | |
| SCHEMBL15023129 | 0.77 | KIF11 (0.46) | NPFFR2IDO1PLA2G7NPFFR1 | |
| SCHEMBL16955558 | 0.75 | KCNA3 (0.37) | KCNA3KMOKCNQ3KCNQ2KCNE1 | |
| SCHEMBL190947 | 0.75 | ALDH1A1 (0.64) | KCNA3ALDH1A1 | |
| SCHEMBL8259273 | 0.75 | TDP1 (0.45) | KCNA3ALDH1A1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | claimed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | claimed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | claimed |
| EP-2121617-A1 | CB1 RECEPTOR MODULATORS | 7TM Pharma A/S (DK) | 2009-11-25 | — | — | EP | claimed |
| WO-2008075012-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2008-06-26 | — | — | WO | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2121617-B1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA AS (DK) | 2014-01-22 | — | — | EP | disclosed |
| EP-2681215-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-20130338140-A1 | SERINE/THREONINE KINASE INHIBITORS | GENETECH, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| WO-2012118850-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | 7TM PHARMA A/S (DK) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338140-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K2, MAP3K20 | KCNA3 3928/4885KMO 4559/4885KCNQ3 4348/4885 |
| US-20100010061-A1 | CB1 RECEPTOR MODULATORS | CNR1, CNR2, GPR6 | KCNA3 861/4885KMO 3832/4885KCNQ3 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.